Advertisement: Wild Knight Vodka
Advertisement: Kao Data Centre mid banner
Advertisement: CJBS mid banner
Advertisement: Excalibur Healthcare mid banner
Advertisement: EBCam mid banner
Advertisement: HCR Hewitsons recruitment mid banner
Advertisement: Mogrify mid banner
Advertisement: RSM mid banner
Advertisement: S-Tech mid banner 3
Advertisement: partnersand mid banner
Advertisement: Simpsons Creative
Barr Ellison Solicitors – commercial property
ARM Innovation Hub
Mid banner advertisement: BDO
Advertisement: TTP
Advertisement: Cambridge Network mid banner
22 October, 2021 - 18:51 By Tony Quested

Bicycle Therapeutics wheels in $201.3m growth capital

Transatlantic biotech game-changer Bicycle Therapeutics is wowing NASDAQ with its 12-month performance and fundraising magic.

Based at the Babraham Research Campus in Cambridge and Massachusetts in the US, the company has just closed a placement of American Depositary Shares which brought in gross proceeds of $201.3 million.

Goldman Sachs & Co. LLC, Morgan Stanley and SVB Leerink acted as joint book-running managers for the offering. JMP Securities acted as co-manager.

Bicycle Therapeutics is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology.
In the last 12 months, the company’s NASDAQ share price has increased 105 per cent while revenue has grown by 31 per cent.

Newsletter Subscription

Stay informed of the latest news and features